---
title: "Absci (ABSI) $100M raise: what Lilly's $40M stake tells us"
url: "https://aibio.space/analysis/absci-absi-lilly-40m-stake-no-discount/"
publisher: "aibio.space"
date: "2026-11-01"
tickers: "NASDAQ:ABSI"
summary: "Absci sold $100M of stock at its $7.41 last sale price, with Eli Lilly taking $40M. The filings disclose no rights for Lilly, so the signal has limits."
---

By aibio.space

[Absci company page](https://aibio.space/companies/absci/)

2026-11-01

# Lilly's $40M Absci deal: what the price signals, and what it doesn't

Absci sold $100M of stock at its $7.41 last sale price, with Eli Lilly taking $40M. The filings disclose no rights for Lilly, so the signal has limits.

[ABSI](https://aibio.space/companies/absci/)

Analysis: opinion, not investment advice

Biotech companies rarely sell stock at the market price. Absci ([ABSI](https://aibio.space/companies/absci/)) did in June, with one large buyer in the book. The AI-led antibody designer sold [13,495,277 shares at $7.41](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281131/d76291d424b5.htm), the same as its last reported sale price on June 23rd, for $100m. Eli Lilly was allocated 5,398,111 of those shares, or $40m. Our news desk [reported the deal](https://aibio.space/news/absci-raises-100-million-7-41-share-eli-lilly-among-buyers/) and [the cash it added](https://aibio.space/news/absci-cash-rises-201-million-after-june-raise-lilly-invests-40-million/). This piece asks what Lilly's cheque buys.

## The terms

The [prospectus supplement](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281131/d76291d424b5.htm) is plain. The price was $7.41, the underwriting discount $0.4446 a share, or 6%, and net proceeds about $93.5m. Jefferies, J.P. Morgan Securities, TD Securities (USA) and Guggenheim Securities were the representatives of the underwriters and book-running managers. After the sale Absci expected 168,845,412 shares outstanding. The money goes to ABS-201, an AI-designed antibody against the prolactin receptor, in hair loss and endometriosis.

On the same day Absci [published interim phase 1 data](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/exhibit991-26x06x23pr.htm) for ABS-201 in 32 healthy volunteers: no serious adverse events at the data cutoff and an estimated half-life of at least 65 days, which supports dosing two or three times in six months. Interim proof-of-concept data in hair loss are due in the second half of 2026.

## How rare a zero discount is

Compare two later deals. Recursion Pharmaceuticals ([RXRX](https://aibio.space/companies/recursion-pharmaceuticals/)), another AI-native developer, sold $200m of stock in October at $3.25, about [13% below its $3.74 last sale](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000134/rxrx-finalprosuppxoct2026o.htm), with no strategic anchor. Viking Therapeutics ([VKTX](https://aibio.space/companies/viking-therapeutics/)) sold 7,857,143 shares [at $35.00](https://www.sec.gov/Archives/edgar/data/1607678/000119312526401384/vktx-20260925.htm) in September, against a last reported sale price of $40.85 on September 22nd in its prospectus, about 14% below by our arithmetic, after strong obesity data. Absci, with early safety data and a smaller market value than either, sold at its last reported sale price and paid the bankers' 6%.

One plausible explanation, ours rather than the company's, is the 40% of the book that Lilly took. A large pharma buyer reduces how much stock the bankers must place with hedge funds that want a discount, and signals scientific interest to everyone else.

## What Lilly gets

Here the filings are quiet. The prospectus mentions Lilly once, as a buyer of $40m of shares. The [8-K filed with the underwriting agreement](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/d139233d8k.htm), the [data release](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/exhibit991-26x06x23pr.htm) and the [second-quarter 10-Q](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm) disclose no board seat, option, right of first negotiation or commercial agreement tied to the stake; the 10-Q does not mention Lilly at all. We found no Schedule 13G from Lilly. That is consistent with the size: 5.4m shares is about 3.2% of the shares outstanding after the deal by our arithmetic, below the 5% level that triggers a 13G, unless Lilly held shares before, which the filings do not say.

So, on the public record, Lilly bought stock on the same terms as everyone else. That is good for other shareholders, because the filings show no extra terms for Lilly. It also makes the signal weaker than the headline suggests. A $40m equity position is a modest sum for Lilly and carries no obligation to partner on ABS-201.

## The criticism

The board, chaired by Frans van Houten [since April 2024](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000078/absi-20260422.htm), and management under chief executive Sean McClain and chief financial officer Zachariah Jonasson (who [signs the 10-Q](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm)) got the stock away at its last sale price. They face questions on two points.

First, disclosure. When a single strategic investor anchors 40% of a raise, shareholders are entitled to a clear statement of whether any side arrangement exists. The filings imply there is none; a sentence saying so would have cost nothing.

Second, concentration of the story. Absci's equity case now leans on ABS-201 and, by association, on the perception that Lilly is interested in it. If the hair-loss proof-of-concept disappoints, the stock has no contractual partner to fall back on. The prospectus also flags that lock-ups for officers and directors include [an exception for sales to cover taxes](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281131/d76291d424b5.htm) on option exercises and vesting, which it says could weigh on the share price.

## What to watch

The interim efficacy readout in hair loss, the start of the endometriosis phase 2, and any filing in which Lilly's role grows beyond that of a shareholder. In June Absci sold stock at its last sale price with a strategic buyer taking 40%. The next raise will show what price the data command without one.

Sources: 424B5 dated June 24th 2026, 8-Ks of June 24th, ABS-201 data release, Q2 10-Q, 2026 proxy, all linked above. Auditor: Ernst & Young LLP, per the 2026 proxy.

## Sources

- [13,495,277 shares at $7.41](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281131/d76291d424b5.htm)
- [published interim phase 1 data](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000118/exhibit991-26x06x23pr.htm)
- [13% below its $3.74 last sale](https://www.sec.gov/Archives/edgar/data/1601830/000160183026000134/rxrx-finalprosuppxoct2026o.htm)
- [8-K filed with the underwriting agreement](https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/d139233d8k.htm)
- [second-quarter 10-Q](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000136/absi-20260630.htm)
- [since April 2024](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000078/absi-20260422.htm)

Every figure comes from the documents above. Chart values come from the company's financial statements as tagged in its SEC filings; derived values are labelled. If you find an error, [tell us](https://aibio.space/reputation/#update).

## Disclosures

1. Every figure carries the as-of date of its source.
2. This analysis was drafted with AI tools from the company's own filings, FDA documents and trial registries. Every number is checked against its source and an editor reviews the piece before it is published.
3. Our method and conflicts policy: [aibio.space/disclosures/](https://aibio.space/disclosures/)

As of 2026-11-01, aibio.space has received no compensation from, and has no paid relationship with, the company covered.

## Investor Chat

Loading posts…

---
Source page: https://aibio.space/analysis/absci-absi-lilly-40m-stake-no-discount/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Absci (ABSI) $100M raise: what Lilly's $40M stake tells us", 2026-11-01, https://aibio.space/analysis/absci-absi-lilly-40m-stake-no-discount/
